G5044

GR 32191B

≥98% (HPLC), solid

• 别名: (4Z)-7-[(1R,2R,3S,5S)-5-([1,1′-Biphenyl]-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid hydrochloride
• 经验公式（希尔记法）: C₃₀H₄₀NO₄Cl
• CAS号: 87248-13-3
• 分子量: 514.10
• MDL號碼: MFCD04113055
• 分類程式碼代碼: 12352200
• PubChem物質ID: 329799744
• NACRES: NA.77

属性

• 化驗: ≥98% (HPLC)
• 形狀: solid
• 顏色: off-white
• mp: 127-128 °C
• 溶解度: H₂O: ~16 mg/mL
• 起源: GlaxoSmithKline
• 運輸包裝: wet ice
• 儲存溫度: −20°C
• SMILES 字串: Cl.O[C@H]1C[C@H](OCc2ccc(cc2)-c3ccccc3)[C@H](CC\C=C/CCC(O)=O)[C@H]1N4CCCCC4
• InChI: 1S/C30H39NO4.ClH/c32-27-21-28(35-22-23-15-17-25(18-16-23)24-11-5-3-6-12-24)26(13-7-1-2-8-14-29(33)34)30(27)31-19-9-4-10-20-31;/h1-3,5-6,11-12,15-18,26-28,30,32H,4,7-10,13-14,19-22H2,(H,33,34);1H/b2-1-;/t26-,27-,28-,30+;/m0./s1
• InChI 密鑰: ZYOBZRTZRQKKNC-UGNABIHOSA-N

说明

生化／生理作用

Selective TP prostanoid receptor antagonist. Inhibits U-46619-induced contraction of guinea pig trachea with IC₅₀=1.8 nM.

特點和優勢

This compound is featured on the Prostanoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

法律資訊

Manufactured and sold under agreement from Glaxo­Smith­Kline

安全信息

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable
• 個人防護裝備: Eyeshields, Gloves, type N95 (US)